Last reviewed · How we verify
Amrubicin hydrocloride
Amrubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents the religation of DNA strands, leading to cell death.
Amrubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents the religation of DNA strands, leading to cell death. Used for Small cell lung cancer, Non-small cell lung cancer.
At a glance
| Generic name | Amrubicin hydrocloride |
|---|---|
| Sponsor | Sumitomo Pharma Co., Ltd. |
| Drug class | Topoisomerase II inhibitor; anthracycline |
| Target | Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Amrubicin is a semi-synthetic anthracycline derivative that binds to DNA and inhibits topoisomerase II, an enzyme essential for DNA replication and transcription. By preventing the re-ligation of DNA breaks, it causes accumulation of DNA damage and triggers apoptosis in rapidly dividing cancer cells. It is structurally related to doxorubicin but has enhanced activity against certain tumor types.
Approved indications
- Small cell lung cancer
- Non-small cell lung cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Cardiotoxicity
- Mucositis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amrubicin hydrocloride CI brief — competitive landscape report
- Amrubicin hydrocloride updates RSS · CI watch RSS
- Sumitomo Pharma Co., Ltd. portfolio CI